With Vioxx , researchers had been warning about the drug 's possible cardiovascular risks since 2000 , only a year after it was approved by the FDA .The FDA said last week after Vioxx was withdrawn that the problems were unique to that drug .The FDA 's own study of the Vioxx safety issue has become mired in controversy .Vioxx was Merck 's fourth top seller , and they knew their decision would be extremely harmful to the company .By contrast , Vioxx made $ 2.5 billion for Merck last year .